LAVAL, QC, March 26, 2019 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced
today that it will report its financial results for the fourth quarter and year ended December 31,
2018 on Monday April 1, 2019 after market close.
Prometic will host a conference call at 11:00am (ET) on Tuesday April 2, 2019. The telephone
numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available as of
Tuesday April 2, 2019 at 2:00pm (ET). The numbers to access the audio
replay are 416-849-0833 and 1-855-859-2056 using the following password (3198209).
A live audio webcast of the conference call will be available via: https://event.on24.com/wcc/r/1969851/0D5A0C85F48EBF7260AFC1BE9877F748
About Prometic Life Sciences Inc.
Prometic (www.prometic.com) is a biopharmaceutical corporation with two drug discovery platforms focusing on unmet
medical needs. The first platform (small molecule therapeutics) stems from the discovery of two receptors which we believe are at
the core of how the body heals: namely, promoting tissue regeneration and scar resolution as opposed to fibrosis. One of the lead
drug candidates emerging from this platform, PBI-4050, is expected to enter pivotal phase 3 clinical trials for the treatment
of Alström syndrome. The second drug discovery and development platform (plasma-derived therapeutics) leverages Prometic's
experience in bioseparation technologies used to isolate and purify biopharmaceuticals from human plasma. The Corporation's
primary goal with respect to this second platform is to address unmet medical needs with therapeutic proteins not currently
commercially available, such as Ryplazim™ (plasminogen). We are also leveraging this platform's higher recovery yield potential
to advance novel and established plasma-derived therapeutics. The Corporation also provides access to its proprietary
bioseparation technologies to enable pharmaceutical companies in their production of non-competing biopharmaceuticals. Recognized
as a bioseparations expert, the Corporation derives revenue from this activity through sales of affinity chromatography media
which contributes to offset the costs of its own R&D investments.
We are headquartered in Laval, Quebec (Canada) and have R&D facilities in Canada, the United Kingdom ("UK") and the United
States ("USA"), manufacturing facilities in Canada and the Isle
of Man and corporate and business development activities in Canada, the USA, Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve
risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the
markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions
turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in
economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2017, under the heading "Risk and Uncertainties related to Prometic's business". As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
View original content: http://www.newswire.ca/en/releases/archive/March2019/26/c1953.html